Teva Pharmaceutical Industries's EPS (Basic) for the
three
months ended in Dec. 2023 was $0.41.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47.
Teva Pharmaceutical Industries's EPS without NRI for the
three
months ended in Dec. 2023 was $1.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.56.
During the past 12 months, Teva Pharmaceutical Industries's average EPS without NRIGrowth Rate was 1.60% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -0.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 3.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -9.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Teva Pharmaceutical Industries's highest 3-Year average EPS without NRI Growth Rate was 76.90% per year. The lowest was -36.60% per year. And the median was 14.00% per year.
Teva Pharmaceutical Industries EPS (Diluted) Historical Data
The historical data trend for Teva Pharmaceutical Industries's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Teva Pharmaceutical Industries Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EPS (Diluted)
-0.91
-3.64
0.38
-2.20
-0.50
Teva Pharmaceutical Industries Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EPS (Diluted)
-1.10
-0.18
-0.77
0.07
0.41
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries PE Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PE Ratio distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Teva Pharmaceutical Industries's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Teva Pharmaceutical Industries EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 